HOME > TOP STORIES
TOP STORIES
-
BUSINESS Moderna Plots Successive Launches in Japan, Updated COVID Jab by Fall: Medical Chief
April 11, 2024
-
REGULATORY Alexion’s Voydeya Marks 1st Application of “Early Launch Premium,” but Rate Fully Axed
April 11, 2024
-
REGULATORY Lagevrio to Get 8.2% Price Cut in July, 2.7% for Kerendia: CEA
April 11, 2024
-
REGULATORY LDP Healthcare Clique Urges Rethink of Rationale for Off-Year Drug Price Revisions
April 10, 2024
-
BUSINESS R&D Jobs Make Up 40% of Pharma New Grads Hires This Spring, Sales Reps Only 20%: Poll
April 9, 2024
-
ORGANIZATION JPMA Launches Website Listing R&D Policies of Members to Help Foster Innovation Ecosystem
April 9, 2024
-
BUSINESS GSK Japan Shooting for 80% Goal for Paid Paternity Leave in 2024
April 8, 2024
-
BUSINESS Kyowa Kirin Hopes Amgen-Partnered Eczema Drug to Rival or Even Eclipse Crysvita in Sales: CEO
April 5, 2024
-
ORGANIZATION PhRMA Hails 2024 Reform, but Says Full Picture Unchanged as 50% of Patented Meds Still Face Cuts
April 4, 2024
-
REGULATORY Opposition Party Head Calls for Rethink of Public Health Coverage in Japan
April 3, 2024
-
COMMENTARY With Honebuto 2024 Looming, Now Is the Time to Revisit Social Security Spending
April 2, 2024
-
BUSINESS New Ono Chief Eager to Go Solo in US, Europe; BTK Med 1st Shield against Opdivo Patent Cliff
April 1, 2024
-
BUSINESS Parexel Helping Japan Address Drug Loss with “Ethnobridging” Studies, PI Still a Hurdle
March 29, 2024
-
REGULATORY MHLW Generic Panel Outlines Plan to Drive Industry Revamp within Specific Time Frame
March 28, 2024
-
REGULATORY Japan Approves Piasky, Beyfortus, Broader Use for Abrysvo, and Lot More
March 27, 2024
-
ORGANIZATION Backed by 12 Pharmas, US Nonprofit’s Cloud Platform Now Up and Running to Streamline Regulatory Submissions
March 26, 2024
-
REGULATORY Chuikyo Agrees to Exempt PD-1/PD-L1, JAK Classes from Spillover Re-Pricing
March 25, 2024
-
REGULATORY Xocova’s Price to Remain Intact after Full Approval, No Change in Clinical Positioning
March 25, 2024
-
REGULATORY Pharma Regulation Panel Wraps Up Debate, Report to Be Finalized Soon
March 22, 2024
-
REGULATORY Japan Resumes Debate on Rx-to-OTC Switch of PPIs after Over 5 Years
March 22, 2024
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
